Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1174C TP53 wild-type |
Therapy | Idasanutlin + Lorlatinib |
Indication/Tumor Type | neuroblastoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174C TP53 wild-type | neuroblastoma | resistant | Idasanutlin + Lorlatinib | Preclinical - Pdx | Actionable | In a preclinical study, a patient-derived xenograft (PDX) model of TP53 wild-type neuroblastoma harboring ALK F1174C was resistant to combination treatment with Lorbrena (lorlatinib) and Idasanutlin (RG7388) (PMID: 36602782). | 36602782 |
PubMed Id | Reference Title | Details |
---|---|---|
(36602782) | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. | Full reference... |